Portal de Periódicos da CAPES

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

2020; Oxford University Press; Volume: 73; Issue: 11 Linguagem: Inglês

10.1093/cid/ciaa1041

1537-6591

Susan Olender, Katherine K Perez, Alan S. Go, Bindu Balani, Eboni G. Price‐Haywood, Nirav Shah, Su Wang, Theresa L. Walunas, Shobha Swaminathan, Jihad Slim, Bum Sik Chin, Christoph Stephan, S Ali, Álex Soriano, Philip A. Robinson, Robert Gottlieb, Tak Yin Owen Tsang, I‐Heng Lee, Hao Hu, Richard Haubrich, Anand P. Chokkalingam, Lanjia Lin, Lijie Zhong, B Nebiyou Bekele, Robertino M. Mera, Chloé Phulpin, Holly Edgar, Joel E. Gallant, Helena Díaz-Cuervo, Lindsey Smith, Anu Osinusi, Diana M. Brainard, José Ignacio Bernardino,

Long-Term Effects of COVID-19

We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard of care.